新型胰腺导管腺癌药物：新兴治疗方法与未来方向。
Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
机构信息
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 DongAn Road, Shanghai, 200032, People's Republic of China.
Department of Oncology, Shanghai Medical College, Fudan University, No. 270 DongAn Road, Shanghai, 200032, People's Republic of China.
出版信息
J Hematol Oncol. 2018 Jan 31;11(1):14. doi: 10.1186/s13045-017-0551-7.
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However, gemcitabine- and 5-fluorouracil-based therapies did not present satisfying outcomes. Novel regimens targeting pancreatic cancer cells, the tumor microenvironment, and immunosuppression are emerging. Biomarkers concerning the treatment outcome and patient selection are being discovered in preclinical or clinical studies. Combination therapies of classic chemotherapeutic drugs and novel agents or novel therapeutic combinations might bring hope to the dismal prognosis for PDAC patients.
过去三十年，胰腺导管腺癌（PDAC）的预后不良与化疗耐药性有关，并未改变。多学科诊断后进行手术和化疗（放疗）是主要的治疗方法。然而，基于吉西他滨和 5-氟尿嘧啶的治疗方案并未取得令人满意的效果。针对胰腺癌细胞、肿瘤微环境和免疫抑制的新方案正在出现。在临床前或临床研究中发现了与治疗结果和患者选择有关的生物标志物。经典化疗药物与新型药物或新型治疗组合的联合治疗可能为 PDAC 患者的不良预后带来希望。
Zotero 插件